/PRNewswire/ SV Health Investors ("SV"), a leading global health care investment firm, is pleased to announce a series of realizations from its growth.
Premium Content
Subscriber only
A MUM’S worry over a teenage daughter dating a man 20 years her senior was the catalyst for a violent driveway confrontation that led to her daughter’s boyfriend being injured when struck with a spanner.
There was no dispute in court evidence that the mother’s then-boyfriend Matthew Peter Manson, aged 38, struck Toby Daniel Williams, 40, with the spanner and caused an arm injury requiring six stitches at Rosewood on Friday, December 13 2019.
At his trial in Ipswich District Court this week, Manson successfully defended the charge of assault causing bodily harm.
After two days of evidence the jury found him not guilty and Manson was discharged.
tbrady@bio.org
Washington, D.C. – As the Biotechnology Innovation Organization (BIO) continues to restructure for a stronger and reinvigorated future, the organization announced new leadership for operations and sustainability.
Shaye Mandle was named Chief Operating Officer (COO), effective March 1, 2021.
Shaye Mandle
With extensive experience in restructuring and rebranding organizations and coming from Minnesota’s Medical Alley Association, Mandle will work to position BIO for the future with aggressive plans to forge enduring partnerships with state organizations, monitor and strengthen internal processes to coincide with BIO’s mission, and reinvigorate BIO’s premier in-person events when it is safe to have them again.
reorganizing the organization s leadership structure.
BIO said the new structure will provide long-term stability for the organization’s ambitious agenda. In a brief statement, McMurry-Heath said the reorganization of BIO’s leadership structure will enable the organization to have a greater focus on its key goals of advocacy, education and collaboration.
“Our excellent leadership team will have the freedom to bring a more laser-like focus to their areas of responsibility, allowing us to accomplish the goals of our strategic vision more efficiently and more effectively,” McMurry-Heath said in a statement.
Some of the new members of the BIO leadership team were quietly put in place before the end of the year, including Chief Financial Officer
New proposed rule offers pathway for USDA, rather than FDA, to oversee regulatory framework for animal biotechnology.
USDA is contemplating taking on regulatory oversight of food animals genetically modified for agricultural purposes. This was previously handled by the Food and Drug Administration who treated genomic modifications as drugs and created significant roadblocks for U.S. companies looking to blaze a path for future disease-resistant and nutritionally enhanced livestock species.
In an advanced notice of proposed rulemaking, the Trump administration announced Dec. 21 its intention for USDA to have primary oversight over gene-edited livestock. Gene editing is seen by those in the industry as a promising new technology that can help farmers breed healthier, more resilient animals, and many within the industry have been asking for USDA to take on the regulatory oversight from FDA.